Trial Profile
An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothelin-expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anetumab ravtansine (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Bayer
- 06 Nov 2019 Status changed from active, no longer recruiting to completed.
- 19 Sep 2019 Planned End Date changed from 28 Oct 2019 to 11 Nov 2019.
- 19 Aug 2019 Planned End Date changed from 26 Sep 2019 to 28 Oct 2019.